



This is a repository copy of *Reply: Intravenous drug use–associated endocarditis complicating research of antibiotic prophylaxis and guideline recommendations*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/143276/>

Version: Accepted Version

Article:

Thornhill, M.H. orcid.org/0000-0003-0681-4083, Dayer, M.J., Chu, V.H. et al. (2 more authors) (2019) Reply: Intravenous drug use–associated endocarditis complicating research of antibiotic prophylaxis and guideline recommendations. *Journal of the American College of Cardiology*, 73 (8). pp. 985-986. ISSN 0735-1097

<https://doi.org/10.1016/j.jacc.2019.01.001>

Article available under the terms of the CC-BY-NC-ND licence
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>



This is a repository copy of *Reply: Intravenous drug use–associated endocarditis complicating research of antibiotic prophylaxis and guideline recommendations*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/143276/>

Version: Accepted Version

Article:

Thornhill, MH orcid.org/0000-0003-0681-4083, Dayer, MJ, Chu, VH et al. (2 more authors) (2019) Reply: Intravenous drug use–associated endocarditis complicating research of antibiotic prophylaxis and guideline recommendations. *Journal of the American College of Cardiology*, 73 (8). pp. 985-986. ISSN 0735-1097 (In Press)

<https://doi.org/10.1016/j.jacc.2019.01.001>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Reply: Intravenous Drug Use Associated Endocarditis Complicating Research of Antibiotic Prophylaxis and Guideline Recommendations

Martin H Thornhill MBBS, BDS, PhD^{a,b}, Mark J Dayer MBBS, PhD^c, Vivian H. Chu MD^d, Patrick T. O’Gara MD^e and Larry M. Baddour MD^f

^aUnit of Oral & Maxillofacial Medicine Surgery and Pathology, School of Clinical Dentistry, University of Sheffield, Sheffield, UK; ^bDepartment of Oral Medicine, Carolinas Medical Center, Charlotte, NC; ^cDepartment of Cardiology, Taunton and Somerset NHS Trust, Taunton, Somerset, UK; ^dDivision of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC; ^eDepartment of Cardiology, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA; ^fDivision of Infectious Diseases and Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN.

Correspondence to:

Prof. Martin Thornhill, Unit of Oral & Maxillofacial Medicine Surgery and Pathology, University of Sheffield School of Clinical Dentistry, Claremont Crescent, Sheffield S10 2TA, UK. Email: m.thornhill@sheffield.ac.uk

Disclosures:

Drs Thornhill, and O’Gara received support from the Delta Dental Research and Data Institute for the submitted work. Dr O’Gara reports receiving support in the last 3 years from Medtronic, Edwards Scientific and the National Heart Lung Blood Institute, that was unconnected to the submitted work; Dr Dayer reports receiving reports from Biotronik in the last 3 years, that was unconnected to the submitted work; none of the other authors report a financial relationship in the previous 3 years with companies that might have an interest in the submitted work. Drs Thornhill, and O’Gara have no nonfinancial interests that may be relevant to the submitted work. Dr Chu reports authorship of ‘UpToDate’, Dr Baddour, as a member of the American Heart Association’s Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, was involved in writing the 2007 American Heart Association guideline on prevention of infective endocarditis; also, he is a paid consultant of Boston Scientific. Dr Dayer was a consultant to the review committee that produced the 2015 update to NICE clinical guideline 64 on prophylaxis against infective endocarditis.

Dr. Eddinger has focused on an important contemporary aspect of the epidemiology of infective endocarditis (IE), which has become a marker of the ongoing opioid epidemic in the United States. As evidenced in Dr. Eddinger's local experience, persons who inject drugs (PWID) now constitute an increasing proportion of patients who develop IE (1,2) and the human and healthcare costs related to such have been unprecedented.

An analysis of PWID within the dataset described in our paper (3) would be of interest and we examined the possibility of doing this. Unfortunately, it is not possible for this to be done without new data abstraction and methodology. As Dr. Edinger points out, a further difficulty is that the ICD-9/10 coding system does not include codes for injection drug use. One is reliant on surrogate markers such as hepatitis C infection (not specific for PWID) or drug dependency/use codes that do not distinguish between injection and non-injection dependency/use. To address this, researchers have implemented different coding algorithms to detect PWID. However, in a study that used two such algorithms, there was a nearly 5-fold difference in the number of PWID-associated IE cases identified (1), highlighting the risk of misclassifying cases using current coding systems.

The disparity in PWID representation in different sectors of the healthcare system, and hence different data sources, is also a problem. A recent North Carolina study (2) found different PWID-associated IE rates between different health insurance payers: Private (12%), Medicare (17%), Medicaid (35%), Self-pay/uninsured (34%), Other/unknown (3%). Since our data only included Private and Medicare-related data, it is likely the impact of PWID-associated IE would have been smaller than had we also included Medicaid and self-pay/uninsured data. Indeed, because we quantified changes in antibiotic prophylaxis prescribing between 2000-2015, we were unable to use Medicaid data (see Methods section) because of a large age-distribution

change in enrollees with Medicaid-covered prescription drug benefits, caused by the transfer of Medicaid patients who were Medicare eligible to Medicare Part D prescription drug coverage in January 2006 (see on-line figure 1c).(3) We were unable, therefore, to include Medicaid data in our study.

Current coding systems are frustrating, as they are inadequate to permit analysis of important healthcare questions like this. Hopefully, coding system changes will allow us to do so in the future.

References

1. Cooper HL, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis. *Clin Infect Dis* 2007;45:1200-3.
2. Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in Drug Use-Associated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017: A Study of Statewide Discharge Data. *Ann Intern Med* 2018.
3. Thornhill MH, Gibson TB, Cutler E et al. Antibiotic Prophylaxis and Incidence of Endocarditis Before and After the 2007 AHA Recommendations. *J Am Coll Cardiol* 2018;72:2443-2454.